A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
Running, not enrolling · Phase 3
Conditions studied: Paroxysmal Nocturnal Hemoglobinuria
In brief
This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.
Key facts
- Study ID
- NCT05389449
- Run by
- Alexion Pharmaceuticals, Inc.
- People needed
- 80
- Starts
- 2022-10-28
- Expected to finish
- 2026-08-24
- Last updated by the study team
- 2026-06-18
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Los Angeles, California, United States
- Research Site — Chicago, Illinois, United States
- Research Site — Baltimore, Maryland, United States
- Research Site — Kansas City, Missouri, United States
- Research Site — Long Island City, New York, United States
- Research Site — Cleveland, Ohio, United States
- Research Site — Dallas, Texas, United States
- Research Site — Porto Alegre, Brazil
- Research Site — Rio de Janeiro, Brazil
- Research Site — Toronto, Ontario, Canada
- Research Site — Brno, Czechia
- Research Site — Lille, France
- Research Site — Paris, France
- Research Site — Pessac, France
- Research Site — Pierre-Bénite, France
- Research Site — Athens, Greece
- Research Site — Thessaloniki, Greece
- Research Site — Haifa, Israel
- Research Site — Jerusalem, Israel
- Research Site — Avellino, Italy
- Research Site — Bassano del Grappa, Italy
- Research Site — Florence, Italy
- Research Site — Milan, Italy
- Research Site — Reggio Calabria, Italy
- Research Site — Roma, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.